Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 16/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360706 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2CASP1CYP2D6ALDH1A1HDAC3 | |
| SCHEMBL3348535 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2CASP1CYP2D6 | |
| SCHEMBL13306578 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2CASP1CYP2D6 | |
| SCHEMBL17148005 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2CASP1CYP2D6 | |
| SCHEMBL645609 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL8764106 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2CASP1CYP2D6 | |
| SCHEMBL646203 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL1409869 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2CASP1CYP2D6 | |
| SCHEMBL13139840 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL6808276 | 0.85 | CASP1 (0.46) | SMN1; SMN2CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138395-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-7041696-B2 | Interleukin-1β converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-7001899-B2 | Interleukin converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1513844-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1511491-A1 | DERIVATIVES OF AZEPINE AND THIAZEPAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511749-A1 | NOVEL INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-20040009966-A1 | 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis | THE PROCTER & GAMBLE COMPANY | 2004-01-15 | — | — | US | disclosed |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003106460-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003104231-A1 | NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003103677-A1 | DERIVATIVES OF AZEPINE AND THIAZERAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009966-A1 | 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis | TST, SYVN1, TXN2 | SMN1; SMN2 3617/4885CASP1 1759/4885CYP2D6 2624/4885 |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1R1, IL1B, IL1RN | SMN1; SMN2 4073/4885CASP1 65/4885CYP2D6 485/4885 |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1B, IL1RN, IL1R1 | SMN1; SMN2 4567/4885CASP1 41/4885CYP2D6 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.